Mizuho Initiates Coverage On Neumora Therapeutics with Outperform Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Mizuho has initiated coverage on Neumora Therapeutics (NASDAQ:NMRA) with an Outperform rating and a price target of $20.
July 08, 2024 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho has initiated coverage on Neumora Therapeutics with an Outperform rating and a price target of $20, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a price target of $20 by Mizuho is likely to boost investor confidence in Neumora Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100